Request Trial
8 July 2025NewsBiotechHa Kung Wong, Venable | Karen Martin, Ipsen | Nitin Virmalwar, Stoke Therapeutics | Jennifer Moitoso, Biogen

WATCH: Mastering the art of IP transactions—due diligence, valuation, and deal-making

LSPN brings together experts from Venable, Ipsen, Stoke Therapeutics, and Biogen to analyse best practices for IP transactions, from due diligence and valuation to structuring deals.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Biotech
Amgen hit with lawsuit over its proposed Opdivo biosimilar
16 September 2026   BMS is stepping up its defence of its blockbuster cancer drug Opdivo as Amgen moves closer to the biosimilar market.
Biotech
Pfizer strikes $10.5 billion oncology deal with Chinese biotech
4 June 2026   The deal gives Pfizer access to 12 early-stage oncology programmes and marks the latest in a growing wave of high-value licensing agreements between Big Pharma and Chinese biotechs.
Biotech
Gilead to pay up to $5bn for antibody-drug conjugates push
8 April 2026   The acquisition of Munich-based biotech gives Gilead ownership of proprietary ADCs tech at a time when pharma and biotech companies are racing to secure next-generation cancer treatments.


Editor's picks

Inside the deal boom: LSIPR’s five-part M&A series—all in one place
Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026

Editor's picks

Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026
Biotech
Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
1 September 2026
Regulation & Industry
The buyers' wishlist: What makes a life sciences deal stack up?
25 August 2026
MedTech
Abbott fends off Chinese rival’s patent challenge at UPC
18 August 2026
Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026
Regulation & Industry
Buying the brains: Why is Big Pharma shopping for innovation?
27 July 2026

More features

Leading European patent litigator to join Carpmaels & Ransford
CIPA Congress: Sustainability is essential for the profession and the planet
Non-profit sues Cambrex over anticancer drug manufacturing trade secrets
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
Amgen hit with lawsuit over its proposed Opdivo biosimilar
Australian biotech sues Grail over multi-cancer blood test
K&L Gates hires six-strong team of IP and corporate lawyers from Pillsbury
Perfect Pitch: Inside the scheme that gets junior lawyers selling to clients